Latest progress in the treatment of schizophrenia with the novel antipsychotic drug Lumateperone
10.3760/cma.j.cn113661-20200326-00144
- VernacularTitle:新型抗精神病药卢美哌隆治疗精神分裂症的新进展
- Author:
Xueying LIU
1
;
Qingmei KONG
;
Tianmei SI
;
Wei HAO
Author Information
1. 北京大学精神卫生研究所 国家精神心理疾病临床医学研究中心（北京大学第六医院） 国家卫生健康委员会精神卫生学重点实验室（北京大学） 100191
- Publication Type:Journal Article
- Keywords:
Antipsychotic agents;
Schizophrenia;
Lumateperone
- From:
Chinese Journal of Psychiatry
2021;54(1):57-61
- CountryChina
- Language:Chinese
-
Abstract:
As a novel antipsychotic drug, lumateperone acts synergistically via serotonergic, dopaminergic, and glutamatergic systems to generate efficacy in positive, negative and depressive symptoms as well. Common adverse reactions are sedation, headache, diarrhea, and dry mouth. Lumateperone has been approved by the U.S. Food and Drug Administration for treatment in adult schizophrenic patients. The pharmacodynamic and the pharmacokinetic profiles, evidence of clinical researches, safety and tolerability of Lumateperone are reviewed in this article.
